NCT03892330

Combination Therapy of Anthracyclines for Children With Nephroblastoma

A Multicenter, Randomized, Double-blind, Prospective Study to Evaluate the Efficacy and Safety of Vincristine, Dactinomycin/Cyclophosphamide Combination Therapy Combined With Liposomal Doxorubicin/Doxorubicin/Pharmorubicin/Pirarubicin in 0.5-14 Year Old Children With Nephroblastoma.

• Status: Not Yet Recruiting
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 120 (estimated)
• Sponsor: Shengjing Hospital · Academic / Other
• Sex: All
• Age: 6 Months – 14 Years
• Healthy volunteers: Not accepted

Summary

This study aims to estimate the efficacy and side effects of study drugs in children with nephroblastoma who are treated with combination therapy.

Conditions

• 0.5-14 Year Old Children With Nephroblastoma

Interventions

Type	Name	Description
DRUG	Vincristine	Dosage according to Children Wilms tumor diagnosis and therapy recommendations: Wilms Tumor-2016 (WT-2016) (2-6) Chemotherapy.
DRUG	Oxytetracycline/ Cyclophosphamide	Dosage according to Children Wilms tumor diagnosis and therapy recommendations: Wilms Tumor-2016 (WT-2016) (2-6) Chemotherapy.
DRUG	Liposomal doxorubicin	The dosage of Liposomal doxorubicin is half of doxorubicin dosage in Children Wilms tumor diagnosis and therapy recommendations: Wilms Tumor-2016 (WT-2016) (2-6) Chemotherapy.
DRUG	Doxorubicin	Dosage according to Children Wilms tumor diagnosis and therapy recommendations: Wilms Tumor-2016 (WT-2016) (2-6) Chemotherapy.
DRUG	Pharmorubicin	The dosage of pharmorubicin is 2 times of doxorubicin dosage in Children Wilms tumor diagnosis and therapy recommendations: Wilms Tumor-2016 (WT-2016) (2-6) Chemotherapy.
DRUG	Pirarubicin	The dosage of pirarubicin is equal to doxorubicin dosage in Children Wilms tumor diagnosis and therapy recommendations: Wilms Tumor-2016 (WT-2016) (2-6) Chemotherapy.

Timeline

• Start date: 2019-06-01
• Primary completion: 2020-12-31
• Completion: 2045-06-30
• First posted: 2019-03-27
• Last updated: 2019-03-27

Locations

1 site across 1 country: China